Following the UK government's new pay offer to NHS consultants, the Royal College of Nursing (RCN) wrote to the Health Secretary Victoria Atkins calling for
fresh negotiations about nursing pay in England last week.
However, the Department of Health and Social Care (DHSC) has rejected their demand, stating that there is no basis to reopen talks as the pay deal was accepted by
the NHS Staff Council.
In the previous pay deal, nurses were given a one-off payment between £1,655 and £3,789 for 2022/23, and a 5 per cent consolidated pay increase for the 2023/24
financial year.
Nursingnotes quoted a DHSC spokesperson as saying: "We hugely value the hard work of NHS nurses and that is why we provided a 5 per cent pay rise.
"We also provided two significant non-consolidated awards, which for nurses at the top of Band 5 was over £2,000, equivalent to an extra 6.1 per cent of their
basic pay.
The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK.
Through this funding, the government aims to create the most advanced genomic healthcare system in the world.
"Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a
£175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC.
The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA.
"£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using
whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC.
"An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing
technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information
such as routine scans.
The Department of Health and Social Care (DHSC) has finally published its response to the 2022 consultation on hub and spoke dispensing.
Considering the consultation evidence and further discussions, the government has expressed its intention to progress the proposals for enabling hub and spoke models
across different legal entities as soon as possible.
This will be achieved by using the enabling powers outlined in Part 2 of the Medicines and Medical Devices Act 2021 (MMDA) to amend the Medicines Act 1968 and the
HMRs.
Furthermore, the DHSC has decided to proceed with the implementation of the two models of hub and spoke dispensing that it consulted on.
The government response to the consultation reads: "Having considered the responses, the government intend to proceed to implement the necessary changes to medicines
legislation to remove the current restrictions that prevent the hub and spoke dispensing models from operating across different legal entities found in section 10 of
the Medicines Act 1968.
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxcarbazepine (Trileptal) 300mg and 600mg tablets on
Wednesday (14 June).
It has notified that the Oxcarbazepine (Trileptal) 300mg tablets will be out of stock from late June 2023 until mid-July 2023 and Oxcarbazepine (Trileptal) 600mg
tablets are out of stock until mid-July 2023.
However, generic oxcarbazepine 300mg and 600mg tablets remain available and will be able to support increased demand.
"Oxcarbazepine (Trileptal) 150mg tablets and generic oxcarbazepine 150mg tablets remain available but cannot support the increase in demand," said DHSC.
"Oxcarbazepine (Trileptal) 60mg/ml oral suspension remains available but cannot meet an increase in demand."
The Department of Health and Social Care (DHSC) has introduced new arrangements for the application of discount deduction to community pharmacy payments which
will be implemented in six financial quarters beginning in October 2022 and concluding in January 2024.
Under the new discount deduction system, the current single scale will be split into three groups: one each for generic medicines, branded medicines, and appliances.
Separate fixed deduction rates have been determined for each group.
This will provide all pharmacies the same rates of deduction applied to their reimbursement for the three different groups, regardless of the total value of that
reimbursement.
Fin McCaul, PSNC member and independent community pharmacy contractor, said: "The discount deduction scale has been a point of contention for contractors for many
years, and PSNC has long been pushing to remedy this.
"The incoming changes are designed to both improve equity of access to margin and manage the distortions presented by branded medicines, which just don't have the
same level of discount available as generics.
The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot
be hoarded or exported from the UK market.
The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs.
In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to
patients across the UK.
The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.
The Department of Health and Social Care (DHSC) has added further 28 new products to the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II
of the Drug Tariff from 1 August 2022.
PSNC said, "It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual
item' criteria and make applications to NHSBSA and DHSC, accordingly."
A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.
Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes
on Tuesday (27 June).
"There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes
Mellitus (T2DM)," said DHSC.
The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to
normal until at least mid-2024.
Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative
treatment options.
The Department of Health and Social Care (DHSC) has issued Serious Shortage Protocols (SSPs) on three HRT medicines to limit dispensing supply to three months.
To ensure women across the UK will be able to more reliably access HRT products SSPs has been issued on the supply of Oestrogel, Ovestin cream and Premique Low Dose.
DHSC stated, "Women who have a prescription for more than three months but are only able to access three months' supply will not have to pay an additional
prescription charge."
"This means women will not incur any additional costs. Imposing a three month limit will mean more women are able to access the medication they want. Any woman
who is worried about access to HRT or is unable to access HRT should speak to her GP."
Recently, Vaccine Taskforce Director General Madelaine McTernan has been appointed to spearhead a new HRT Supply Taskforce, applying lessons learned from the
successful procurement seen during the Covid vaccination programme to identify ways to support the HRT supply chain ensuring it can meet both short and long
term demand. The move will save time for patients as well as pharmacists and prescribers who are working tirelessly to tackle the covid backlog.
Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure.
The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection
in pre-filled pen will be out of stock from early May until mid-July 2024.
"The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations," it said.
However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024.
Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.
The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) for Salazopyrin EN-Tabs 500 mg due to ongoing shortage of the medicine.
With SSP014 in place from today (November 26), for every prescription one Sulfasalazine 500mg gastro-resistant (GR) tablet will be supplied.
This SSP will expire on December 20, 2021, and PSNC will update contractors in case of any change.
PSNC has advised pharmacists to notify the patient's prescriber while supplying in accordance with this SSP.
Besides, the supervising pharmacist should refer back to the prescriber if a non-chewable atorvastatin tablet would not be appropriate for the patient.
Campaigners have submitted an open letter to the Department of Health and Social Care (DHSC), urging the Minister for Primary Care and Public Health to
freeze prescription charges to keep people with long-term conditions alive and well.
The campaign is led by the Prescription Charges Coalition, which represents over 50 organisations, including Royal Pharmaceutical Society (RPS) and Pharmacists'
Defence Association (PDA).
Currently, the prescription charge is £9.65 per item, and campaigners have asked the government to freeze it for 2024 and 2025 as people living with long-term
health conditions in England are "being forced to choose between heating, eating, and taking their vital medication on a daily basis."
In 2023, a study conducted by the Prescription Charges Coalition revealed that almost 10 per cent of survey participants had skipped medication in the previous
year due to the cost of prescriptions. This led to increased physical and mental health problems, as well as impacted the time they took off work.
Laura Cockram, Chair of the Prescription Charges Coalition and Head of Campaigns at Parkinson's UK, expressed deep concern that a further rise in the charge this
year will lead to people skipping or not taking the full dose of their medication, which will affect their health and put more pressure on the already under
pressure NHS.
Department of Health and Social Care (DHSC) has issued a supply notification for Varicella vaccine (live) powder and solvent for suspension/solution for
injection 0.5ml vials (Varivax and Varilrix) until mid-October.
AAH have put quotas in place for GPs to limit the ordering of Varilrix and safeguard supplies during this shortage. To override this quota or obtain stock in any
other primary care setting (including community pharmacy) a prescription will be required.
To obtain stock through the prescription validation system pharmacy will have to contact AAH Quota Management Customer Care team:
Online https://www.aah.co.uk/s/quotarequest or by logging into AAH Point https://www.aah.co.uk/s/signin then choose Additional Services and select Quotas.
The pharmacy should follow the steps and fill in the required information including their email address.
The pharmacy can also call: 0344 561 8899 and select option 3 (quota)
The pharmacy will need to have the prescription details available
The AAH team will review the request and follow the guidance provided below to validate the prescription and approve the order.
Community pharmacies in England will continue to receive the free protective equipment (PPE) as the Government's scheme has been extended for another year until
March 2024.
The Department of Health and Social Care (DHSC) has announced that it will continue to supply all categories of PPE, free of charge, for frontline health and social
care staff according to demand until the end of March 2024, or when stocks run out.
Last year, DHSC implemented a new and improved portal platform for eligible providers to access free COVID-19 related PPE supplies.
The Pharmaceutical Services Negotiating Commitee (PSNC) said: "Community pharmacy teams can continue to order PPE from the NHS PPE portal for free for as long as
stock is available."
Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update.
While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed.
The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses.
It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.
The Pharmaceutical Services Negotiating Committee (PSNC) has called for improved workforce planning to be undertaken by the government and NHS.
However, for this to happen, it added, "high quality workforce data for community pharmacy needs to be available."
For this reason, the Department of Health and Social Care (DHSC), NHS England and PSNC have agreed that it will be a Terms of Service requirement for contractors
to complete the annual Health Education England (HEE) community pharmacy workforce survey, which will then provide a full picture of the community pharmacy workforce,
including identifying the number of vacancies and regions where these are particularly hard to fill.
PSNC said: "It is acutely aware of the challenges that contractors and their teams are currently facing, so in recognition of the workload associated with completing
the annual workforce survey, we have negotiated with DHSC and NHS England that the requirement to undertake an annual patient satisfaction survey will be removed from
the Terms of Service from 1st October 2022."
This means that contractual requirement will no longer apply to contractors in 2022/23 and going forward.
The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available
to purchase potentially life-saving drugs early.
This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments
Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or
save their lives.
"The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people
renewed hope for a better future."
A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients.
DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with
few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to
the smaller patient cohort.
In a move to make healthcare more accessible, the Department of Health and Social Care (DHSC) has announced plans to empower pharmacy technicians, dental
therapists, and hygienists with enhanced authority following two public consultations run by the government in 2023.
Revealed by Primary Care Minister Andrea Leadsom on Thursday 28th March, this strategic decision promises to usher in "a faster, simpler, and fairer access to
primary care" by granting pharmacy professionals "the ability to both supply and administer medications".
Based on the public consultations that garnered widespread support, with 97% backing the empowerment of dental hygienists and therapists and 84% favouring similar
rights for pharmacy technicians, the new reform is aimed to cut through bureaucratic red tape and bolster efficiency in patient care.
Dental hygienists and therapists, under the proposed change, will be empowered to administer select medications, including pain relief and fluoride, without the
need for dentist approval.
The Pharmaceutical Services Negotiating Committee (PSNC) has rejected Department of Health and Social Care (DHSC) and NHS England's proposal on price
concessions reform and relief measures to ease pressure on pharmacies.
The Committee called the proposal 'insufficient' to meet the sector's needs considering the impact of the current crisis, reflecting on the economic pressures
that accelerated through the autumn and winter.
The Ministers and other decision-makers have shown their interest in the potential role of community pharmacy, particularly in using a Pharmacy First approach
and making use of PGDs and the skills of independent prescribers.
But the Committee had made clear to them that without new money this is all a pipedream. "We need an urgent injection of funds into the sector, otherwise we will
continue to see a degradation of services and eventual collapse of the network. The Committee is clear that there is no further place for warm words while pharmacy
collapses," said PSNC.
The Committee reflected that the 5-year CPCF agreement had been based on working together to create the capacity and context necessary to deliver the shift towards
greater service delivery. Not only has that capacity-release not happened due to slow progress by Government, but pharmacies have also been burdened with these
additional, and insurmountable, challenges.
The Department of Health and Social Care (DHSC) is pushing ahead with its plans to implement a new drug tariff from April 2024. However, this move has
sparked strong opposition from Community Pharmacy England (CPE), raising concerns about its potential impact on pharmacies and patients.
Earlier, it was announced that the April drug tariff will include the new 'Retrospective top-up payment for Concessionary prices, which will be applied
automatically for the products listed in Part VIIIE each quarter by the NHS Business Services Authority (NHSBSA), according to the volume the contractor was
paid for.
However, CPE argued that the government has imposed these "untested" changes without their agreement, and strongly opposed them stating that "no recovery or
downward pressure on margin is acceptable given the financial fragility of community pharmacies."
Janet Morrison, chief executive of CPE, has voiced strong opposition to these changes, arguing that "any system expecting pharmacies to dispense at a loss"
jeopardises the sector's financial stability and compromises patient care.